Tracing pathway activities with kinase inhibitors and reverse phase protein arrays

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Aberrant protein kinase activity is implicated in various diseases, notably cancer.
• Developing effective kinase inhibitors is a major focus in pharmaceutical research.
• Existing methods for profiling kinase inhibitors can be complex and time-consuming.

Purpose of the Study:

• To present a novel chip-based reverse phase protein array (RPA) platform for profiling kinase inhibitors.
• To demonstrate the utility of this RPA platform in cell-based assays for compound screening.
• To establish a sensitive and efficient method for characterizing kinase inhibitors.

Main Methods:

• Utilized a chip-based reverse phase protein array (RPA) platform integrated with planar waveguide technology.
• Performed cell-based assays using A431 cell lysates to analyze signaling pathways.
• Employed a microtiter-plate format for cell culture, treatment, and lysis.

Main Results:

• Achieved an absolute limit of detection (LOD) down to the low zeptomole range.
• Successfully profiled kinase inhibitor activity by analyzing key effectors in epidermal growth factor (EGF) and insulin signaling pathways.
• Validated the RPA platform as a suitable tool for compound screening in a microtiter-plate format.

Conclusions:

• The chip-based RPA platform is a valuable screening tool for characterizing large numbers of kinase inhibitors.
• The technology enables efficient profiling of inhibitors across a wide range of cellular signaling pathways.
• The reverse array format facilitates rapid development of site-specific phosphorylation assays with reduced antibody requirements compared to ELISA systems.